Our results showed that PD-L1 was highly expressed on CD103+CD11c+ DCs in tumor-draining lymph nodes, which are known to be specialized APCs capable of presenting tumor antigens to CD8+ T cells, and that the anti-PD-L1 mAb treatment enhanced T cell priming in the tumor-draining lymph nodes in a tumor antigen-specific manner. Here, ITGAX is linked to neoplasm.